Attendee search 

Depomed, Inc. (Nasdaq:  DEPO) is a US based specialty pharmaceutical company with a focus in pain, CNS, and Women's Health.  The company has advanced three products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations

Depomed is currently seeking US co-promotion, and Global license partners for it's marketed product Gralise (once-daily gabapentin for Post Herpetic Neuralgia), and Serada a non-hormonal treatment for Vasomotor Symptoms (menopausal hot flashes) which is currently under in registration.

CalciMedica is a clinical stage biotechnology company dedicated to the discovery and development of oral drugs to treat inflammatory and autoimmune diseases and organ transplant rejection. CalciMedica’s compounds are selective and potent inhibitors of the calcium release-activated calcium (CRAC) channels. The CRAC channel activates a signaling pathway that is essential for the adaptive immune response in T cells. The therapeutic value of inhibiting this pathway has been established by calcineurin inhibitors, a class of immunosuppressants that work downstream from the CRAC channel. Furthermore, the CRAC channel has been validated as a drug target in humans through the identification of a loss-of-function mutation. CalciMedica has discovered several potent and selective CRAC channel inhibitors (CCIs) that show anti-inflammatory activity in animal models. CalciMedica is developing its first clinical compound, CM2489, for the treatment of moderate-to-severe plaque psoriasis. CalciMedica recently completed a multiple-dose Phase 1 study with CM2489 in psoriasis patients and shown it to be safe, well-tolerated, and well-behaved with evidence of clinical improvement. CM2489 is the first CRAC channel inhibitor, or CCI, to be tested in humans. CalciMedica's pipeline of structurally diverse, potent and selective CRAC channel inhibitors has the potential to become a therapeutic platform, targeting multiple autoimmune indications.